Ethnic‐specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high‐dose methotrexate
Cancer · 2023
DOI: 10.1002/cncr.34646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Rachel D Harris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neurotoxicity Syndromes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Background
High‐dose methotrexate (HD‐MTX; 5000 mg/m 2 ) is an important component of curative therapy in many treatment regimens for high‐risk pediatric acute lymphoblastic leukemia (ALL). However, methotrexate therapy can result in dose‐limiting neurotoxicity, which may disproportionately affect Latino children. This study evaluated risk factors for neurotoxicity after HD‐MTX in an ethnically diverse population of patients with ALL.
Methods
The authors retrospectively reviewed the medical records of patients who were diagnosed with ALL and treated with HD‐MTX at Texas Children's Cancer Center (2010–2017). Methotrexate neurotoxicity was defined as a neurologic episode (e.g., seizures or stroke‐like symptoms) occurring within 21 days of HD‐MTX that resulted in methotrexate treatment modifications. Mixed effects multivariable logistic regression was used to estimate the odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between clinical factors and neurotoxicity.
Results
Overall, 351 patients (58.1% Latino) who received 1183 HD‐MTX infusions were evaluated. Thirty‐five patients (10%) experienced neurotoxicity, 71% of whom were Latino. After adjusting for clinical risk factors, the authors observed that serum creatinine elevations ≥50% of baseline were associated with a three‐fold increased odds (OR, 3.32; 95% CI, 0.98–11.21; p = .05) for neurotoxicity compared with creatinine elevation
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
- Texas Children's Hospital, Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
ORCID-Profile: Rachel D Harris, Philip J Lupo, Karen R Rabin, Austin L Brown
Förderung
- NCI NIH HHS
- NIH HHS
- NIGMS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Harris, R. D., Bernhardt, M. B., Zobeck, M. C., Taylor, O. A., Gramatges, M. M., Schafer, E. S., Lupo, P. J., Rabin, K. R., Scheurer, M. E., & Brown, A. L. (2023). Ethnic‐specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high‐dose methotrexate. Cancer. https://doi.org/10.1002/cncr.34646
Vancouver
Harris RD, Bernhardt MB, Zobeck MC, Taylor OA, Gramatges MM, Schafer ES, et al. Ethnic‐specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high‐dose methotrexate. Cancer. 2023. doi:10.1002/cncr.34646
BibTeX
@article{Harris2023,
author = {Harris, Rachel D and Bernhardt, Melanie Brooke and Zobeck, Mark C and Taylor, Olga A and Gramatges, Maria Monica and Schafer, Eric S and Lupo, Philip J and Rabin, Karen R and Scheurer, Michael E and Brown, Austin L},
title = {Ethnic‐specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high‐dose methotrexate},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34646}
}
EUVIMED